Skip to content
Nobel Jews
Portrait of Gerald M. Edelman
Photo: Bernard Gotfryd, This image is available from the United States Library of Congress's Prints and Photographs division under the digital ID gtfy.01178.This tag does not indicate the copyright status of the attached wo · Public domain via Wikimedia Commons

Nobel Prize in Physiology or Medicine · 1972

Gerald M. Edelman

He worked out the chemical structure of antibodies, the immune system's Y-shaped defenders, laying groundwork for antibody medicines.

The Nobel citation: “for their discoveries concerning the chemical structure of antibodies”
Born
July 1, 1929, New York, NY, USA
Died
May 17, 2014, La Jolla, CA, USA
Shared with
Rodney R. Porter
Affiliation at the time
Rockefeller University, USA

Medicine prize

1972

Shared with 1 other laureate.

Age that year

43years

Born in 1929.

Headline credited impact

300,000–1.2 millionpeople benefited

People treated with monoclonal antibody medicines worldwide. How it was built

Sources cited

32

Fact-checked September 24, 2026.

  • As a bored army doctor in Paris, he read an immunology book in a library and decided antibodies, not the molecules they attack, were the real puzzle.
  • In 1969 his team finished the full sequence of an antibody, about 1,300 amino acids long, the longest protein sequence worked out at that time.
  • The antibody they decoded, known as Eu, came from the blood of a myeloma patient, Mr. Eubanks. Reference charts still number antibody positions by the 'Eu' system.
  • He won the Nobel Prize at 43, then left immunology to study embryos and, finally, how the brain gives rise to the mind.
  • As a boy he studied violin seriously with Albert Meiff, who had trained alongside Jascha Heifetz, before deciding he did not want to perform.

The breakthrough

Taking antibodies apart to reveal their chemical structure

Antibodies are proteins in the blood that grab onto invaders such as bacteria and viruses. By the late 1950s scientists knew they were huge molecules, but not how they were built, or how the body could make one to fit almost any invader. Edelman guessed that an antibody was several protein chains held together by sulfur bridges. In 1959 he broke those bridges with chemicals and showed that the molecule fell apart into smaller chains. Working separately in England, Rodney Porter cut antibodies with an enzyme instead. Together their results led to the now-famous Y-shaped model: two long 'heavy' chains and two short 'light' chains. Edelman then found a shortcut. Patients with a blood cancer called multiple myeloma pour out huge amounts of one single antibody, and in 1962 he and his colleague Joseph Gally showed that the odd protein in these patients' urine was simply a spare light chain. That gave chemists pure material to study. By 1969 his team had read the entire sequence of one antibody, about 1,300 amino acids. Think of a set of keys: every key has the same handle, but the teeth are cut differently. Antibodies are similar. The stem is the same from one antibody to the next, while the tips vary. This fitted the idea that the body keeps a vast stock of different antibodies and multiplies the cells whose antibodies fit an invader.[3],[4],[6],[7],[16],[19]

“Science is imagination in the service of the verifiable truth and that service is indeed communal.”
Gerald M. Edelman, From his speech at the Nobel Banquet in Stockholm, 10 December 1972.[5]

What it meant for humanity

Antibodies are the proteins the immune system uses to tag invaders. Doctors had long relied on them in blood tests, yet little was known about their chemical structure. Edelman's and Porter's work showed that every antibody shares the same basic frame and differs mainly at its tips. It also gave a chemical basis to the leading explanation of how the body can make antibodies against almost anything: it keeps a vast stock of different ones and multiplies the cells that happen to fit. The Nobel committee said the discoveries set off intense research around the world, with practical results for diagnosis and treatment.

The longest-lasting benefit is in medicine. Today's antibody drugs are designed around the parts that structural work mapped. Chimeric drugs such as rituximab, for lymphoma, join the variable tips of a mouse antibody to the constant stem of a human one. Humanized drugs keep only the small mouse loops that touch the target. More than 200 antibody medicines are now on the market, for conditions from breast cancer and lymphoma to asthma and high cholesterol. Reference databases still number positions in human antibodies by the 'Eu' system, based on the molecule Edelman's team sequenced in 1969.

Edelman's later work also mattered. His group discovered cell adhesion molecules, which help cells stick together as an embryo takes shape and as a nervous system is built. He then helped bring consciousness back as a serious subject for brain science. Those contributions changed how scientists think rather than producing medicines.

  • Showed in 1959 that an antibody is made of several protein chains, not one, which helped reveal its Y shape of two heavy and two light chains.[3],[4]
  • Led the team that in 1969 determined the complete amino acid sequence of an antibody, about 1,300 amino acids, the longest protein sequence known at the time.[7],[19]
  • Antibody medicines are designed around the variable and constant parts that this structural work revealed: chimeric drugs pair mouse variable regions with human constant regions.[23]
  • Reference databases still number positions in human antibodies by the 'Eu' system, based on the antibody Edelman's team sequenced from a myeloma patient's blood.[7],[15],[22]
  • More than 200 antibody medicines are now on the market, with nearly 1,400 more in clinical testing.[28]
  • His laboratory discovered cell adhesion molecules, surface proteins that help cells stick together as embryos and nervous systems form.[2],[17]

Impact in numbers

Edelman's main legacy is understanding. He and Rodney Porter turned antibodies from a vague blood fraction into molecules with a known architecture, and the Nobel committee said this gave immunology a solid footing for systematic research for the first time. That architecture, a constant stem and variable tips, is the blueprint antibody engineers still work from, so we record a small ripple share of the shared outcome for antibody medicines, using the same totals as the César Milstein profile. The share is kept low because the medicines also needed hybridomas, genetic engineering, target discovery and decades of drug development, and because other groups were closing in on the same structure. Diagnostic uses of antibodies, his discovery of cell adhesion molecules and his influence on the science of consciousness are real but cannot be counted honestly, so we make no numerical claim for them.

HealthFundamental scienceEconomy

Each number is the laureate’s credited share of a real-world outcome, cumulative to 2025. The whole outcome, the share of credit, and the reasoning are shown so you can check the arithmetic. Outcomes shared with other laureates are counted once on the impact page.

  • Low confidenceRippleModeledHealth

    People treated with monoclonal antibody medicines worldwide

    300,000–1.2 million

    people benefited, credited share

    That is 2% of 15–60 million people benefited since 1986.

    How this number was built

    Whole-outcome range reused from the shared outcome in the Milstein profile. Floor: Roche reports rituximab treated over 2.7M people by 2017 and tocilizumab over 1M by 2019; if those two of 200+ antibodies are at most a quarter of all patients, the total is about 15M. High: rituximab's 2019 sales ($6.54B) were about 4.4% of a roughly $150B market; 2.7M / 0.044 = about 60M. People treated, not cured. Share 0.02: chimeric and humanized drugs are built on the variable/constant architecture Edelman and Porter revealed, but hybridomas (Kohler and Milstein), antibody engineering, target discovery and drug development did most of the work, and others were near the same structure (for example, the variable and constant regions were first seen in light-chain sequences from other laboratories). We give the Edelman-Porter structure work 0.04 in total, split equally with Porter.[23],[27],[28],[29],[30],[31]

    Sources: Roche; Roche; BioDrugs (via PubMed Central); Journal of Biomedical Science (via PubMed Central); Nature Biotechnology (via PubMed Central); mAbs (via PubMed Central)

  • Low confidenceRippleModeledEconomy

    Cumulative global sales of monoclonal antibody medicines (a proxy for economic activity)

    $40–52

    billion in economic value, credited share

    That is 2% of $2–2.6 trillion in economic value since 1986.

    How this number was built

    Range reused from the shared outcome in the Milstein profile. Sourced annual sales: about $39B (2008) and $75B (2013), $115.2B (2018), $217.3B (2021). Linear interpolation gives about $1.39T for 2008-2021. Low: add 2022-2025 flat at $217B a year ($0.87T), ignore earlier years, then cut 10% for Fc-fusion drugs counted in these totals: about $2.0T. High: add about $0.18T for 1998-2007 and 8% yearly growth for 2022-2025 (the forecast rate in Ecker 2015): about $2.6T. Nominal dollars, which understates the 2024-dollar value; sales measure spending, not net benefit. Share 0.02 as for the patients claim.[23],[26],[27]

    Sources: mAbs (via PubMed Central); Journal of Biomedical Science (via PubMed Central); Nature Biotechnology (via PubMed Central)

The double edge

No weapons or deliberate harms are linked to Edelman's work. The controversies were scientific and institutional. His theory of the brain, which he called neural Darwinism, drew sharp criticism. Francis Crick labeled it 'neural Edelmanism', and the biologist Gunther Stent said he could not follow it, though colleagues later argued that its overall spirit had held up. The Neurosciences Institute he founded depended on private donors and struggled for money; in 2012 it cut its laboratory research and left its celebrated building. More broadly, the antibody medicines that grew partly out of this structural knowledge are often very expensive.

  • Minor

    A contested theory of the brain

    In 1989 Francis Crick published a critique titled 'Neural Edelmanism', saying readers found Edelman's book hard to grasp and hard to relate to existing ideas. The biologist Gunther Stent said he did not understand the theory either. Later colleagues argued that parts of it were borne out as neuroscience turned to the activity of large groups of neurons.[8],[9],[24]

  • Minor

    An institute that ran short of money

    Edelman funded his Neurosciences Institute from philanthropists rather than government grants. In 2012 it dropped its experimental work, auctioned nearly 400 lots of laboratory equipment and moved out of its building into rented offices. Edelman said it was not closing but taking a new direction.[8],[25]

  • Minor

    Antibody medicines are costly

    A 2026 study of 57 antibody drugs, using US Veterans Affairs prices, found an average of about US$127,430 per course or year of treatment, with 42% priced above US$100,000, which puts many out of reach for patients who must pay themselves.[31]

Against the odds

Edelman's own path was comfortable compared with that of Jewish laureates who fled Europe, and the sources consulted do not describe him meeting antisemitism. His father, a doctor who had survived polio, chose to practice in a poor neighborhood and insisted his son attend a local public school rather than an elite private one. Edelman got into Ursinus College partly because his sister knew the dean. The wider climate for Jewish Americans who wanted to become doctors was harsher. From the 1920s most US medical schools capped Jewish admissions, and the caps were firmly in place by 1945. In an era when Jews may have made up a third to a half of applicants, Jewish students rarely exceeded one in ten places at most schools. After the Second World War, investigations in New York and Philadelphia exposed the quotas, and by 1970 they were gone. Edelman entered the University of Pennsylvania's medical school in Philadelphia in 1950, while they were still common.

  • 1950

    Quota

    Edelman entered medical school in Philadelphia in 1950, when most US medical schools still limited Jewish admissions. Investigations in Philadelphia and New York helped expose the quotas, which had ended by 1970. No source says a quota affected his own admission.[2],[20],[21]

  • —

    Other

    Edelman's father, a physician born in Philadelphia, had been one of the early polio cases there. He chose to practice in a poor neighborhood and sent his son to the local public high school rather than an elite private school.[12]

Jewish background

Both parents JewishCulturally Jewish

Edelman was born in Queens, New York, to Edward Edelman, a physician, and Anna Freedman Edelman, who worked in insurance. Wikipedia describes both parents as Jewish, and he has an entry in the Encyclopaedia Judaica. We found no source on the family's religious practice, and a 2007 profile in the San Diego Jewish Journal described him as firmly secular. His links to Jewish life appear cultural: he sat on the Board of Governors of Israel's Weizmann Institute of Science, and a scientist he mentored remembered his fondness for Jewish jokes.[2],[8],[9],[17],[18],[32]

Key dates

  1. July 1, 1929

    Born in New York City and raised in Ozone Park, Queens, and Long Beach, New York; his father was a physician.[1],[9],[12]

  2. 1950

    Graduates magna cum laude from Ursinus College in Pennsylvania and marries Maxine Morrison.[2],[13]

  3. 1954

    Earns his MD from the University of Pennsylvania, then trains at Massachusetts General Hospital.[2]

  4. 1955

    Serves as a US Army doctor in Paris, where an immunology book in the American Library turns him toward antibodies.[2],[14]

  5. 1957

    Joins the Rockefeller Institute in New York as a graduate fellow in Henry Kunkel's laboratory; earns his PhD in 1960.[2],[11]

  6. 1959

    Shows that antibodies split into separate protein chains when their sulfur bridges are broken.[3],[4]

  7. 1962

    With Joseph Gally, shows that Bence Jones proteins from myeloma patients are antibody light chains.[3],[16]

  8. 1969

    His team reports the complete amino acid sequence of an entire antibody molecule and proposes that it is folded into compact domains.[3],[7],[15]

  9. 1972

    Shares the Nobel Prize in Physiology or Medicine with Rodney Porter for discoveries on the chemical structure of antibodies.[1],[4]

  10. 1977

    He and his colleagues discover cell adhesion molecules, proteins that help cells bind to one another as tissues and nervous systems form.[2],[17]

  11. 1981

    Founds the Neurosciences Institute, an independent nonprofit research center based at Rockefeller University.[8],[9],[25]

  12. 1987

    Publishes Neural Darwinism, setting out his theory that the brain develops and learns by selecting among groups of neurons.[2],[8]

  13. 1992

    Moves to the Scripps Research Institute in La Jolla, California, bringing the Neurosciences Institute with him.[8],[10],[11],[25]

  14. May 17, 2014

    Dies at home in La Jolla, California, aged 84; he had Parkinson's disease and prostate cancer.[1],[9]

Sources

  1. 1.Gerald M. Edelman - Facts · NobelPrize.org (Nobel Prize Outreach)
  2. 2.Gerald M. Edelman - Biographical (with 2005 addendum) · NobelPrize.org (from Les Prix Nobel en 1972, Nobel Foundation, 1973), 1973
  3. 3.Antibody Structure and Molecular Immunology (Nobel Lecture, 12 December 1972) · NobelPrize.org, 1972
  4. 4.The Nobel Prize in Physiology or Medicine 1972 - Press release · Karolinska Institutet / NobelPrize.org, 1972
  5. 5.Gerald M. Edelman - Banquet speech (10 December 1972) · NobelPrize.org, 1972
  6. 6.Award ceremony speech, Nobel Prize in Physiology or Medicine 1972 (Sven Gard) · NobelPrize.org, 1972
  7. 7.The covalent structure of an entire gammaG immunoglobulin molecule (Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ), PNAS 63(1):78-85 · Proceedings of the National Academy of Sciences (via PubMed Central), 1969
  8. 8.Darwin's neuroscientist: Gerald M. Edelman, 1929-2014 (Anil K. Seth), Frontiers in Psychology 5:896 · Frontiers in Psychology (via PubMed Central), 2014
  9. 9.Gerald M. Edelman, Nobel Laureate and 'Neural Darwinist,' Dies at 84 (Bruce Weber) · The New York Times (archived copy, Internet Archive), 2014
  10. 10.In Memoriam: Gerald Edelman (1929 - 2014) · The Scripps Research Institute, News&Views, 2014
  11. 11.Nobel laureate and longtime faculty member Gerald Edelman dies at 84 · The Rockefeller University, 2014
  12. 12.Gerald Edelman - Love of music in early childhood (recorded interview, story 1) · Web of Stories
  13. 13.Gerald Edelman - Getting into science (recorded interview, story 3) · Web of Stories
  14. 14.Gerald Edelman - The American Library in Paris and going to the Rockefeller Institute (recorded interview, story 9) · Web of Stories
  15. 15.Gerald Edelman - Completing work on the structure of gamma globulin molecule (recorded interview, story 22) · Web of Stories
  16. 16.Gerald Edelman - An epiphany working on Bence Jones protein (recorded interview, story 19) · Web of Stories
  17. 17.Edelman, Gerald Maurice (Encyclopaedia Judaica entry) · Encyclopaedia Judaica, via Encyclopedia.com
  18. 18.Gerald Edelman · Wikipedia
  19. 19.Gerald M. Edelman (World of Microbiology and Immunology; Encyclopedia of World Biography) · Encyclopedia.com
  20. 20.Why Did the United States Medical School Admissions Quota for Jews End? (Halperin EC), Am J Med Sci 358(5):317-325 · American Journal of the Medical Sciences (via PubMed), 2019
  21. 21.Jewish American Heritage Month: The Forgotten History of Quotas in American Medical School Admissions · George Washington University, Himmelfarb Health Sciences Library, 2023
  22. 22.Correspondence between the IMGT unique numbering for C-DOMAIN, the IMGT exon numbering, the Eu and Kabat numberings: Human IGHG · IMGT, the international ImMunoGeneTics information system
  23. 23.Development of therapeutic antibodies for the treatment of diseases (Lu RM et al.), Journal of Biomedical Science 27:1 · Journal of Biomedical Science (via PubMed Central), 2020
  24. 24.Neural edelmanism (Crick F), Trends in Neurosciences 12(7):240-248 · Trends in Neurosciences (via PubMed), 1989
  25. 25.Neuroscience institute to move from architectural icon into office space (Monya Baker) · Nature News Blog (archived copy, Internet Archive), 2012
  26. 26.The therapeutic monoclonal antibody market (Ecker DM, Jones SD, Levine HL), mAbs 7(1):9-14 · mAbs (via PubMed Central), 2015
  27. 27.Biopharmaceutical benchmarks 2022 (Walsh G, Walsh E), Nature Biotechnology 40:1722-1760 · Nature Biotechnology (via PubMed Central), 2022
  28. 28.Antibodies to watch in 2025 (Crescioli S et al.), mAbs 17(1):2443538 · mAbs (via PubMed Central), 2024
  29. 29.FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers · Roche, 2017
  30. 30.FDA approves Roche's Rituxan (rituximab) in children with two rare blood vessel disorders · Roche, 2019
  31. 31.The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities (Motta-Santos AS et al.), BioDrugs 40(3):517-537 · BioDrugs (via PubMed Central), 2026
  32. 32.The Brain Doctor: Dr. Gerald Edelman is a Genius on a Spiritual Path (Judd Handler) · San Diego Jewish Journal (archived copy, Internet Archive), 2007

Fact-checked on September 24, 2026 by a separate AI fact-checking pass that re-opened the sources, with 6 corrections made. How we check

Suggest a correction